

DAY 2: Tuesday, Sept. 20

Discovery Bioanalysis & New Technologies Workshop

7:30 - 8:30 AM **Registration & Breakfast**
8:30 - 8:40 AM **Workshop Introduction**
Violet Lee, Genentech

SESSION I: Advancements in AAV, mRNA, and Lipid Nanoparticle Technology for Viral and Gene Therapies

8:50 - 8:45 AM **Session Introduction**
Katie Matys, PPD & Chris Kochansky, Exelixis

8:45 - 9:10 AM **Programming T Cell Therapies for Solid Tumors is Enabled by Precise Delivery of Large and Modular Gene Circuits with Multiple Therapeutic Functions**
Aaron Cooper, Arsenal Bio

9:10 - 9:15 AM **Q & A**

9:15 - 9:40 AM **Bioanalytical Strategies and Challenges for CAR-T Support**
Nanda Balasubramanian, BMS

9:40 - 9:45 AM **Q & A**

9:45 - 10:20 AM **PLENARY: Immunogenicity Prediction: How Does This Fit In Drug Development?**
Steve Swanson, Genentech

10:20 - 10:30 AM **Q & A**

10:30 - 10:55 AM **Break**

10:55 - 11:15 AM **SPONSOR SHOWCASE**

11:15 - 11:20 AM **Plenary Introduction**
Violet Lee, Genentech

11:20 - 11:55 AM **PLENARY: The Role of Single-Cell and Single-Molecule Proteomics in Therapeutic Development**
Parag Mallick, Nautilus Biotechnology

11:55 - 12:05 PM **Q & A**

12:05 - 1:05 PM **LUNCH**

SESSION II: Bioanalysis of Oligonucleotide Therapeutics

1:05 - 1:10 PM **Session Introduction**
Hiroshi Sugimoto, Takeda & Jing Tu, Alliance Pharma

1:10 - 1:35 PM **Bioanalytical approach for Diverse Oligonucleotide Therapeutics using Multiple Bioanalytical Platform**
Hisao Shimizu, Takeda

1:35 - 1:40 PM **Q & A**

1:40 - 2:05 PM **Hyphenated liquid chromatography techniques and qPCR: Overcoming the Bioanalytical Challenges of Oligonucleotide Therapeutics and mRNA Vaccines**
Laixing Wang, Chongqing Denali Medpharma and Helens Clinical Research Center

2:05 - 2:10 PM **Q & A**

2:10 - 2:40 PM **Break & Poster Presentation**

SESSION III: Beyond the Rule of Five: Considerations in Bioanalysis and Data Analysis

2:40 - 2:45 PM **Session Introduction**
Dieter Drexler, BMS & Jonathan Josephs, Genentech

2:45 - 3:10 PM **Development of a Target Engagement (TE) Assay for the Oral Peptide PCSK9-LDLr Inhibitor Program**
Weixun Wang, Merck

3:10 - 3:15 PM **Q & A**

3:15 - 3:40 PM **To Infinity and Beyond Rule of Five Compounds: Challenges and Considerations for Discovery Stage Bioanalytical Support**
Yueting Wang, AbbVie

3:40 - 3:45 PM **Q & A**

3:45 - 4:10 PM **Expanding the Protein Degradation Toolbox**
Jacques Saarbach, Yale

4:10 - 4:15 PM **Q & A**

4:15 - 5:30 PM **Reception & Poster Presentation**

